Free Trial
OTC:AKBLF

ALK-Abelló A/S (AKBLF) Stock Price, News & Analysis

ALK-Abelló A/S logo
$25.30 +4.72 (+22.90%)
As of 10:38 AM Eastern

About ALK-Abelló A/S Stock (OTC:AKBLF)

Key Stats

Today's Range
$25.31
$25.31
50-Day Range
$19.90
$21.35
52-Week Range
$17.90
$27.03
Volume
2,084 shs
Average Volume
200 shs
Market Capitalization
N/A
P/E Ratio
N/A
Dividend Yield
N/A
Price Target
N/A
Consensus Rating
N/A

Company Overview

ALK-Abelló A/S operates as an allergy solutions company in Europe, North America, and internationally. Its product portfolio includes GRAZAX/GRASTEK, RAGWITEK/RAGWIZAX, ACARIZAX/ODACTRA, MITICURE, CEDARCURE, and ITULAZAX/ITULATEK for treatment of allergic rhinitis and allergic asthma. The company offers allergy immunotherapy products in the form of injections, sublingual drops, and tablets for the treatment of various allergies, including grass, ragweed, house dust mite, Japanese cedar, tree, and food. It also provides consumer healthcare solution, which include Digital eco-system, a platform which connect and engages with allergy sufferers in the disease journey through tools and e-commerce offerings that supports, guidance and relief, and smoothing the path to allergy immunotherapy treatment. In addition, the company offers diagnostic allergy solutions through testing by skin prick test or blood test; and emergency treatment, such as intra-muscular injection of adrenaline for the treatment of acute life-threatening allergic reactions, including Anaphylaxis. The company has a collaboration with Torii Pharmaceutical Co., Ltd. to develop, market and distribute allergy immunotherapy tablet for the treatment of grass pollen allergy. ALK-Abelló A/S was founded in 1923 and is headquartered in Horsholm, Denmark.

Receive AKBLF Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for ALK-Abelló A/S and its competitors with MarketBeat's FREE daily newsletter.

AKBLF Stock News Headlines

ARS Pharma in pact with ALK-Abelló to co-promote neffy
ALK-Abello says FDA approves label expansion for Odactra
URGENT: Someone's Moving Gold Out of London...
People who don’t understand the gold market are about to lose a lot of money. Unfortunately, most so-called “gold analysts” have it all wrong… They tell you to invest in gold ETFs - because the popular mining ETFs will someday catch fire and close the price gap with spot gold.
ALK-Abello shares rise following 4Q earnings report
See More Headlines

AKBLF Stock Analysis - Frequently Asked Questions

ALK-Abelló A/S's stock was trading at $22.35 on January 1st, 2025. Since then, AKBLF stock has decreased by 11.0% and is now trading at $19.90.
View the best growth stocks for 2025 here
.

Shares of AKBLF stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services.

Industry, Sector and Symbol

Stock Exchange
OTC
Sector
Medical
Industry
Biotechnology
Sub-Industry
N/A
Current Symbol
OTC:AKBLF
CIK
N/A
Fax
N/A
Employees
2,824
Year Founded
N/A

Profitability

Trailing P/E Ratio
N/A
Forward P/E Ratio
N/A
P/E Growth
N/A
Pretax Margin
N/A

Debt

Sales & Book Value

Annual Sales
N/A
Price / Cash Flow
N/A
Price / Book
N/A

Miscellaneous

Free Float
N/A
Optionable
Not Optionable
Beta
N/A
7 Stocks to Buy And Hold Forever Cover

Enter your email address and we'll send you MarketBeat's list of seven stocks and why their long-term outlooks are very promising.

Get This Free Report

This page (OTC:AKBLF) was last updated on 5/6/2025 by MarketBeat.com Staff
From Our Partners